Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
about
Abuse of amphetamines and structural abnormalities in the brainVesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistryMethamphetamine toxicity and messengers of deathVesicular monoamine transporter 2: role as a novel target for drug developmentPotential adverse effects of amphetamine treatment on brain and behavior: a reviewNeuropharmacological mechanisms underlying the neuroprotective effects of methylphenidateCatecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disordersThe newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicityGlial modulators as potential treatments of psychostimulant abuseCellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cellsThe Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.Genetically correlated effects of selective breeding for high and low methamphetamine consumption.Behavioral genetic contributions to the study of addiction-related amphetamine effects.The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in miceMethamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substratesA tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.HIV-1 gp120 and drugs of abuse: interactions in the central nervous systemReduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosisMethamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration.Methamphetamine toxicity and its implications during HIV-1 infection.Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice.The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatumLong-term effects of a single adult methamphetamine challenge: minor impact on dopamine fibre density in limbic brain areas of gerbilsVMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processingMethamphetamine induces endoplasmic reticulum stress related gene CHOP/Gadd153/ddit3 in dopaminergic cellsVMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discriminationPrior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.Enhanced neurodegeneration after a high dose of methamphetamine in adenosine A3 receptor null mutant miceMechanisms of methamphetamine-induced dopaminergic neurotoxicity.A guide to neurotoxic animal models of Parkinson's diseaseIncreased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine ToxicityProfound reduction in sensitivity to the aversive effects of methamphetamine in mice bred for high methamphetamine intake.Monoamine transporters: vulnerable and vital doorkeepers.Male/Female differences in neuroprotection and neuromodulation of brain dopamine
P2860
Q22241673-004A8621-7949-47F9-860D-2CB0E492167FQ24601233-53792E3F-3315-407F-A2F4-70387F67FC77Q24647617-88F3E9E4-1F94-4DA3-8F50-D06CB872F350Q24647764-56DC1E34-23D0-48B8-BE3E-944DA0AD2A0BQ24657966-C5030347-124D-4F77-AC4A-60766A98470AQ24658233-65CEFDB4-5F43-486D-B529-03BDC8829F3CQ26826093-8EC7AA92-188D-4960-BD18-9826F60E1A6EQ28261448-15062D9F-8FB2-46BF-9DF3-072FBBED75C8Q28307030-BB955E5E-9867-41B2-8107-9CAF9730479BQ28387863-45E5B887-B730-4DA2-9BB6-7F0BDCD6CED3Q30430534-6F9DBD8F-36BB-4AC2-8BF4-8AB7AD9B4A53Q30443801-E25CDB20-C74A-42B2-BC84-59065CA0061EQ30491913-14016514-11F0-4B67-9B9A-D71BD66F9533Q30494693-BF8EE9F5-8392-4D9D-8A9B-5387F4E98268Q30497495-119CB019-7ED9-473D-A90D-5A863F2FAB7DQ30523813-BA06FB78-104A-4524-A811-3E4E5C6C7A3AQ33608570-38B5B184-A95D-489B-8E32-F7A73770FF08Q33747909-55F78F80-2D4B-4B3A-9084-5812148CA8C9Q33861553-6D18AE7E-91A6-4317-A7F0-763891899D4EQ33862898-725F81E0-3DFD-4818-B44B-731106362CC4Q33958279-8D6B64C8-6E10-42A6-B298-55D1EDB5D0D5Q33985461-E53881CC-5EDB-4B38-B92B-765E51330D14Q34214699-EA9F725C-EC55-41CA-9E6B-CAF5AA3FE25BQ34217427-888040D1-C39A-43C5-BC0F-5ECB019294FFQ34281043-02F213E5-6E8D-48C5-8ACF-548D61DF625BQ34557273-CB626357-DBF0-40EF-B681-77EF90E29E88Q34595165-A2830FF3-5612-4283-A013-6E51FA87B305Q34760266-00DF83D8-1B3E-415F-A33D-5E5E3E3A4DCBQ35007339-66484BAD-2BBF-49A0-8F63-6AF907531C5BQ35031572-E3FBEEFE-082E-4FDD-8724-BCE799A56F46Q35141831-FB1A01EC-8C2E-4A9F-B3C0-81D024B39400Q35191319-E2438829-8342-48A9-AF2B-A5DF3EC6AE0AQ35287229-A5351839-DF64-4397-9943-CCEC41410FCBQ35569786-2DB3FE41-8738-49AE-AC7D-258308FB98B0Q35594901-D14A9C88-4FB4-40C7-BC63-5BF8BB98F0F0Q35603488-28BDFBCA-E43C-418C-984E-CAC73330F981Q35810975-2C2E3C63-BCB3-4E48-BC2A-4A218CB4CAF5Q35814827-4E7EA952-04CE-47D3-A471-00F4B1E952B4Q35877150-0E5E8900-893C-466F-835E-FFE22D2AD2DCQ35972056-0ED9F6E5-C867-484A-B4D4-DE9026A724F2
P2860
Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@en
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@nl
type
label
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@en
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@nl
prefLabel
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@en
Increased methamphetamine neur ...... transporter 2 knock-out mice.
@nl
P2093
P1476
Increased methamphetamine neur ...... e transporter 2 knock-out mice
@en
P2093
F Fumagalli
G W Miller
K J Valenzano
P304
P356
10.1523/JNEUROSCI.19-07-02424.1999
P407
P577
1999-04-01T00:00:00Z